Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evolent HealthFRA:9EH +3.06%63 EV-to-FCF is 2,259.48 as of Jul. 21, 2026. GuruFocus rates FRA:9EH with a GF Score™ of 63/100 and a GF Value™ of €9.69 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 405 Healthcare Providers & Services companies, Evolent Health ranks worse than 98.52% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Evolent Health's Enterprise Value is €1,326 Mil.
Evolent Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €1 Mil. Therefore, Evolent Health's EV-to-FCF for today is 2,259.48.
The historical rank and industry rank for Evolent Health's EV-to-FCF or its related term are showing as below:
FRA:9EH'
s EV-to-FCF Range Over the Past 10 Years
Min: -4661.27 Med: -20.75 Max: 1576.02
Current: 1082.73
During the past 13 years, the highest EV-to-FCF of Evolent Health was 1576.02. The lowest was -4661.27. And the median was -20.75.
FRA:9EH's EV-to-FCF is ranked worse than 98.52% of 405
companies
in the Healthcare Providers & Services industry
Industry Median: 18.06
vs FRA:9EH: 1082.73
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Evolent Health's PE Ratio (TTM) for today is calculated as:
Evolent Health's share price for today is €5.05.
Evolent Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.072.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Evolent Health EV-to-FCF Related Terms
Evolent Health EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Evolent Health's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Evolent Health's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolent Health EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Evolent Health's EV-to-FCF falls into.
Evolent Health's current Enterprise Value is €1,326 Mil.
Evolent Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolent Health (FRA:9EH) has a EV-to-FCF of 2,259.48 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Evolent Health and its competitors. According to the industry distribution chart, Evolent Health ranks #399 out of 405 companies in the Healthcare Providers & Services industry, placing it in the top 98.5%.
Is Evolent Health's EV-to-FCF too high?
Evolent Health's current EV-to-FCF is 2,259.48. The Healthcare Providers & Services industry median EV-to-FCF is 18.06. Evolent Health's value of 2,259.48 is 12411% above this industry median. Based on the distribution chart, Evolent Health ranks #399 out of 405 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Evolent Health has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolent Health's EV-to-FCF compare to PHR and CTEV?
According to the Healthcare Providers & Services industry distribution chart, Evolent Health ranks #399 out of 405 companies for EV-to-FCF. This places Evolent Health in the lower half of its industry. The industry median EV-to-FCF is 18.06. Evolent Health's value of 2,259.48 is 12411% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 18.06, based on 405 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evolent Health's current EV-to-FCF of 2,259.48 is 12411% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Evolent Health and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 18.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolent Health's current EV-to-FCF is 2,259.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolent Health stock overvalued right now?
Based on GuruFocus' analysis, Evolent Health (FRA:9EH) is currently considered Possible Value Trap. The stock's GF Value™ is €9.69, compared to a current price of €5.05 — trading 47.9% below its estimated fair value. The current EV-to-FCF is 2,259.48 and 12411% above the Healthcare Providers & Services industry median of 18.06. Evolent Health's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Evolent Health (FRA:9EH), the current EV-to-FCF is 2,259.48 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolent Health (FRA:9EH) Overvalued in 2026?
Based on GuruFocus' analysis, Evolent Health stock appears to be undervalued.
The current stock price of €5.05 is trading 47.9% below its estimated GF Value™ of €9.69.
GuruFocus considers Evolent Health to be Possible Value Trap.
Key valuation signals for FRA:9EH:
EV-to-FCF: 2,259.48
GF Value™: €9.69 vs. price of €5.05 (47.9% below fair value)
Industry Position: 12411% above the Healthcare Providers & Services median (#399 of 405)
No single metric tells the full story. See the FRA:9EH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
63GF Score
Get the complete analysis for FRA:9EH
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9EH has been successfully added to your 
